Please check your mail in a few minutes for our welcome email and Free Report. If you do not see an email from us, please check your spam folder and add to your approved/whitelist (or just click "not spam").

Email a Friend
Decrease text size Increase text size

Carnitine for Peyronie’s Disease Treatment

Carnitine for Peyronie’s Disease Treatment

Carnitine for Peyronie's Disease TreatmentCarnitine for Peyronie’s Disease Treatment is a substance the body makes naturally in the liver and kidneys and then stores in the heart, brain, sperm, and skeletal muscles. Because it acts as an antioxidant and may help restore cells damaged by inflammation, it is frequently suggested as a treatment for various conditions, including Peyronie’s disease.

Study of Carnitine for Peyronie’s Disease Treatment

Only one study of Carnitine for Peyronie’s Disease Treatment has been done to evaluate the use of acetyle-L-carnitine in Peyronie’s disease. The study involved 48 patients who were given either 20 mg twice daily of tamoxifen or 1 gram twice daily of acetyl-L-carnitine for three months. Acetyl-L-carnitine was significantly more effective than tamoxifen at reducing pain and inhibiting progression of the disease, and both drugs were effective at reducing plaque size. Acetyl-L-carnitine significantly reduced penile curvature as well, from 15.9 degrees to 8.9 degrees. However, no follow-up studies were ever conducted to duplicate or verify this finding. (Biagiotti 2001)

Dose and Side Effects of Carnitine for Peyronie’s Disease Treatment

The suggested dose of Carnitine for Peyronie’s Disease Treatment is 1 gram twice daily for three months. Carnitine supplements are available in three forms: L-carnitine, which is the most widely available; acetyl-L-carnitine, often used for brain disorders; and propionyl-L-carnitine, typically used for heart disease and peripheral vascular disease. Side effects are generally mild and may include restlessness, insomnia, vomiting, headache, and stuffy nose. Rare side effects include body odor, rash, fever, and increased blood pressure.


Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie’s disease: a preliminary report. BJU Int 2001 Jul; 88(1): 63-67 Carnitine for Peyronie’s Disease Treatment

About Dr. Larry Lipshultz, M.D.

Dr. Lipshultz is Professor of Urology and Chief of the Division of Male Reproductive Medicine and Surgery at the Baylor College of Medicine in Houston, Texas . He is an internationally acclaimed fertility specialist and a pioneer in the field of urologic microsurgery, specializing in male infertility, erectile dysfunction, microsurgery, genetic causes of infertility, and age-related changes in male hormone levels (androgen replacement). He was a founder of the Society for the Study of Male Reproduction and is a Past President of the American Society for Reproductive Medicine. In addition, he has served on the FDA Advisory Committee for Reproductive Health Drugs. He was the first AUA Research scholar and was awarded the prestigious Hugh Hampton Young Award at the 2005 AUA Annual Meeting. More on Dr. Lipshultz

Site last updated 21 October, 2016



Likebox Slider Pro for WordPress